Real‐World Treatment Patterns in AERD: An Analysis of ATAD, Biologics, and Combination Therapy
Open Access
- 21 November 2025
- journal article
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (1) , 99-101
Abstract
Key Points: Contemporary aspirin exacerbated respiratory disorder (AERD) therapy commonly includes aspirin desensitization (55%) and biologics (48%). Aspirin desensitization therapy has higher discontinuation rates than biologics. Patients receiving biologics are younger, and ∼25% of the patients switch to other agents.Keywords
This publication has 6 references indexed in Scilit:
- Co‐treatment of non‐steroidal anti‐inflammatory drug‐exacerbated respiratory disease with dupilumab and aspirin therapy after desensitizationClinical & Experimental Allergy, 2023
- Aspirin-exacerbated respiratory diseaseAnnals of Allergy, Asthma & Immunology, 2023
- Aspirin desensitization and biologics in aspirin-exacerbated respiratory diseaseAnnals of Allergy, Asthma & Immunology, 2022
- Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil countJournal of Allergy and Clinical Immunology, 2022
- Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory DiseaseThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup AnalysisAmerican Journal of Rhinology & Allergy, 2021